-+ 0.00%
-+ 0.00%
-+ 0.00%

JUNSHI BIOSCIENCES ANNOUNCES ACCEPTANCE OF THE SUPPLEMENTAL APPLICATION FOR TORIPALIMAB PLUS CHEMOTHERAPY AS PERIOPERATIVE TREATMENT FOR RESECTABLE STAGE Ⅱ-Ⅲ NSCLC

Reuters·07/21/2026 23:10:13

Please log in to view news